Immunovant, Inc. · NASDAQ:IMVT
Immunovant — Corporate Update (June 2021)
17 slides from Immunovant's corporate update, Jun 1, 2021
Slide 1: Corporate Update Conference Call
Corporate Update Conference Call June 1, 2021 Exhibit 99.2
Slide 2: Forward-looking statements
2 Forward-looking statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “expect,” “plan,” “anticipa
Slide 3: Roivant 13D
Roivant 13D 3 The special committee has retained Centerview Partners as its financial advisor and Wachtell, Lipton, Rosen & Katz as its legal advisor. In March of this year, Roivant, our 57% stockholder, amended its Schedule 13D to state that it intends to make a proposal to us to acquire the outsta
Slide 4: Agenda – things we've learned and next steps
4 Agenda – things we’ve learned and next steps Patient needs vary by indication and disease severity • Different diseases will require different regimens to address • Maintenance therapy requires strong immune suppression while acute dosing often requires very strong immune suppression Updated 1401
Slide 5: Improved understanding of the antibody creates more opportunity to address unmet needs
Improved understanding of the antibody creates more opportunity to address unmet needs Updated IMVT-1401 profile is exciting 5 01 02 03 04 IMVT-1401 is more potent than expected, with a broader therapeutic window IgG, Albumin, and LDL are tightly linked which leads to predictable patient responses F
Slide 6: Meaningful IgG reductions at all doses
Meaningful IgG reductions at all doses: 340 is a high dose, 680 a very high dose, 255 strong New data demonstrate stronger potency and broad therapeutic window 6Note: Data in figure from ASCEND GO-2 trial of IMVT-1401 in Thyroid Eye Disease -100 -80 -60 -40 -20 0 20 0 2 4 6 8 10 12 14 16 18 20 Ig G
Slide 7: Lipid elevations correlated tightly with albumin change
Lipid elevations correlated tightly with albumin change and magnitude similar across indications 7 Both albumin and LDL return to baseline post cessation of treatment Albumin and LDL are tightly linked Predictability valuable to patients and physicians Predictability eases patient management
Slide 8: 255mg dose results in modest changes to LDL & albumin, with potent IgG knockdown
2.0 2.5 3.0 3.5 4.0 4.5 5.0 0 2 4 6 8 10 12 14 16 18 20 M ea n A lb um in (g /d L) Week Placebo 255 mg QW 12w SC 340 mg QW 12w SC 680 mg QW 12w SC 255mg dose results in modest changes to LDL & albumin, with potent knockdown in IgG Data suggest favorable trade-off in IgG reductions vs. LDL/Albumin No
Slide 9: Varied dosing regimens to optimize the risk/benefit profile of IMVT-1401
Varied dosing regimens, have potential to optimize the risk/benefit profile of IMVT-1401… Potency and broad therapeutic window enable multiple paths forward 9 Moderate and high dose offer flexibility for chronic dosing High dose and very high dose offer flexibility for induction Standard dose regime
Slide 10: HCP feedback consistently suggests LDL impact is manageable
10 HCP feedback consistently suggests LDL impact is manageable 1. Source: HCP survey, N=16 (March 2021) Data below refer to anticipated market share based on hypothetical LDL profile The likelihood to prescribe a hypothetical anti-FcRn without an LDL impact and with an LDL impact of 30% is similar.
Slide 11: LDL was controlled in patients who entered on statins
LDL was controlled in patients who entered on statins (a post-hoc analysis) 1. Data presented based on exploratory analyses performed on stored samples 2. Week 6-12 timepoints; each subject shown at the point of maximal duration of blinded treatment period for IMVT-1401 • Across a variety of doses a
Slide 12: Return to Clinic Planned in Multiple Indications
Return to Clinic Planned in Multiple Indications
Slide 13: Early data in WAIHA trial demonstrates promise of IMVT-1401
Our outlook on IMVT-1401 efficacy and potential of FcRn class has improved Early data in WAIHA trial demonstrates promise of IMVT-1401 1. Note: All data from ASCEND WAIHA, a Phase 2 trial of IMVT-1401 in Warm Autoimmune Hemolytic Anemia Previous WAIHA therapy 1st line – prednisolone 2nd line – cyclo
Slide 14: Thyroid Eye Disease Summary
• We observed declines in total IgG and in Thyroid Stimulating Antibodies throughout treatment • Approximately 41 subjects reached the 13-week primary endpoint at the time of study termination vs. 77 planned. The study was therefore significantly underpowered to demonstrate efficacy • We observed ch
Slide 15: IMVT-1401: A robust pipeline in a product
IMVT-1401: A robust pipeline in a product T a r g e t I n d i c a t i o n 2H21 1H22 2H22 A n t i c i p a t e d M i l e s t o n e s Myasthenia Gravis (MG) Phase 3 initiation expected in late 2021 or early 2022 Thyroid Eye Disease (TED) Study start TBD Warm Autoimmune Hemolytic Anemia (WAIHA) Phase 2a
Slide 16: Strengthened executive leadership team
Immunovant is proud to welcome Bill Macias Strengthened executive leadership team 16 New Chief Medical Officer Bill Macias, MD, PhD
Slide 17: Patient needs vary by indication, severity and stage of disease
Patient needs vary by indication, severity and stage of disease Short-term, deep IgG reduction (up to 80%) often required Long-term, strong IgG suppression (up to 60%) in chronic setting New Onset of Disease Maintain Disease Control Acute Conditions Best efficacy with the least immunosuppression Tre